- Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
- Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
- Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
- Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
- Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
- Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
- Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
- Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
- Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
More ▼
Key statistics
On Friday, Minerva Neurosciences Inc (NERV:NAQ) closed at 2.44, 6.56% above its 52-week low of 2.29, set on Apr 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.45 |
---|---|
High | 2.49 |
Low | 2.43 |
Bid | 2.42 |
Offer | 2.50 |
Previous close | 2.43 |
Average volume | 16.91k |
---|---|
Shares outstanding | 6.99m |
Free float | 5.44m |
P/E (TTM) | -- |
Market cap | 17.04m USD |
EPS (TTM) | -4.65 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 20:37 BST.
More ▼